Bluefin Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bluefin Capital Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-51,559	Closed	-$2.48M	–	544
2020 Q1	$2.48M	Buy	51,559 +25,160	+95%	+$1.17M	0.32%	64
2019 Q4	$1.24M	Buy	+26,399	New	+$1.17M	0.08%	201

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Bluefin Capital Management's RARX Position: Q2 2020 in Review

Bluefin Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 51,559 shares — an estimated $2.48M sold.

Bluefin Capital Management first reported a position in RARX in Q4 2019 and held it in 2 quarters. The position peaked at $2.48M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Bluefin Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Bluefin Capital Management sold 51,559 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.48M.
Bluefin Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Bluefin Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.48M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Bluefin Capital Management's 13F filing for Q2 2020, filed 17 Aug 2020.